Table 1.
Overview of demographic data, clinical scores and p-alpha-syn deposition (number of sites and percentage of structures positive for p-alpha-syn) of patients with RBD, PD and normal controls
| RBD with normal FP-CIT-SPECT | RBD with pathological FP-CIT-SPECT | PD | Healthy controls | |
|---|---|---|---|---|
| Number (n), gender (male/female) | 8; 6 male, 2 female | 10; 9 male, 1 female | 25; 14 male, 11 female | 20; 8 male, 12 female |
| Median age (years) (quartiles) | 62 (57.75/69.25) | 65 (59.5/66.75) | 63 (59/67) | 59 (52/69) |
| Median RBD-SQ (quartiles) | 10 (8.75/10.5) | 10 (7.5/10) | – | – |
| Median MoCA (quartiles) | 28 (26.5/29.5) | 26 (24.75/28.25) | – | – |
| Median BDI (quartiles) | 16 (12.75/20.25) | 8·5 (2.75/17.5) | – | – |
| Patients with p-alpha-syn deposition | 3 (37.5%) | 7 (70%) | 20 (80%) | 0 |
| Median percentage of p-alpha-syn-positive structures (quartiles) | 0 (0/6.10) | 2.25 (0.15/6.16) | 3.67 (1.63/7.00) | 0 |
| Median number of p-alpha-syn-positive biopsy sites (quartiles) | 0 (0/2) | 1 (0.25/2.5) | 2 (1/3) | 0 |
| Median duration of RBD (years) (quartiles) | 3.5 (1.95/6.25) | 5.5 (3.75/7.75) | – | – |
| Median UPDRS 1 (quartiles) | 3 (1/5.75) | 2.5 (1.75/4) | 4.5 (4/8) | – |
| Median UPDRS 2 (quartiles) | 1 (0.25/2.5) | 0 (0/1) | 4 (3/4) | – |
| Median UPDRS 3 (quartiles) | 2.5 (0.75/4.75) | 1 (0/2.75) | 19 (11.75/21.25) | – |
| Median NMS (quartiles) | 10 (7.5/11.75) | 8 (4.5/12.5) | 28 (14/33) | – |
| Median TDI (quartiles) | 23.88 (14.88/30.25) | 12 (6/23.94) | – | – |
BDI Beck Depression Inventory, FP-CIT-SPECT 123I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl)-nortropane Single photon emission computed tomography, NMS non-motor symptom score, p-alpha-syn phosphorylated alpha-synuclein, PD Parkinson’s disease, RBD REM sleep behaviour disorder, RBD-SQ RBD screening questionnaire, UPDRS Unified Parkinson’s Disease Rating Scale